Find More Contacts for Gemmus Pharma
Protected Content
CEO
Executive Management
1 email found
View contacts for Gemmus Pharma to access new leads and connect with decision-makers.
View All Contacts
  • Company Type For Profit
  • Contact Email incoming@gemmuspharma.com
  • Phone Number 4159781908

Gemmus Pharma is a drug development company founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and

Infectious Disease (NIAID) and has completed a Series A round. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.

Lists Featuring This Company

Health Care Startups (Top 10K)
9,900 Number of Organizations • $229.2B Total Funding Amount • 45,467 Number of Investors
San Francisco Bay Area Companies With Fewer Than 100 Employees (Top 10K)
9,835 Number of Organizations • $184.6B Total Funding Amount • 55,670 Number of Investors
San Francisco Companies With Fewer Than 50 Employees (Top 10K)
9,992 Number of Organizations • $50.9B Total Funding Amount • 30,231 Number of Investors
Western US Startups Founded in 2007
243 Number of Organizations • $5.7B Total Funding Amount • 631 Number of Investors

Frequently Asked Questions

Where is Gemmus Pharma's headquarters? Gemmus Pharma is located in San Francisco, California, United States.Who invested in Gemmus Pharma? Gemmus Pharma has 5 investors including Wilmington Investor Network and The Angels' Forum.How much funding has Gemmus Pharma raised to date? Gemmus Pharma has raised .When was the last funding round for Gemmus Pharma? Gemmus Pharma closed its last funding round on May 13, 2014 from a Series B round.Who are Gemmus Pharma's competitors? Alternatives and possible competitors to Gemmus Pharma may include CEL-SCIInovio Pharmaceuticals, and Apellis Pharmaceuticals.